Potential Role for Topical Antiandrogens in the Management of Acne Among Patients Receiving Masculinizing Hormone Therapy

To the Editor We read with interest the recent phase 3 clinical trial data¹ and Barbieri’s accompanying Editorial² on the use of clascoterone, a novel topical antiandrogen, in treating moderate to severe facial acne. In the Editorial,² Barbieri highlights the need to identify specific subgroups or acne phenotypes for which topical antiandrogens may be most effective. Of critical consideration, and not discussed in either the clinical trial¹ or Editorial,² topical antiandrogens may be particularly helpful for managing acne in individuals receiving masculinizing hormone therapy (MHT).